Earnings per share for the last twelve months: Advanced Biomed Inc. (ADVB)
Advanced Biomed Inc (ADVB) efficiency is based on the precision of chips for early cancer detection via blood. The company's annual revenue per unit demonstrates a trend where the value -0.08 reflects current dynamics. Premium pricing is supported by unique diagnostic microfluidics. The R&D cycle is currently stable, focusing on preclinical tests of rapid systems and the implementation of analytical software.
Financial and market metric breakdowns for Advanced Biomed Inc. (ADVB)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Advanced Biomed Inc|ADVB - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Advanced Biomed Corp|ADVB - Company Debts|Debts to Book Capitalization Advanced Biomed Inc|ADVB - Company Long-Term Debts|Company Short-Term Debt Advanced Biomed|Quick Ratio advanbiomed.com
- net income and valuation multiples indicators:
ADVB - Net Income|Projected Future Earnings Advanced Biomed Inc|ADVB - Market Cap to Earnings|Forward P/E Multiple Advanced Biomed Corp|ADVB - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Advanced Biomed Inc|ADVB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Advanced Biomed|ADVB - Earnings per share for the last twelve months|Quarterly EPS earnings growth advanbiomed.com|ADVB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Advanced Biomed Inc
Fundamental company valuation:advanbiomed.com (ADVB)
This indicator reflects the portion of net income attributable to a single common share over the last twelve months. Investors assess the real return on equity using the rolling trailing twelve-month earnings per share to identify operational compression. The metric's trend captures the business's financial resilience relative to borrowing costs. For Advanced Biomed Inc (ADVB), this confirms the effective monetization of microfluidic technologies. The high switching costs for clinics migrating to their cloud software ensure steady growth of this fundamental parameter.
Competitors of Advanced Biomed Inc (ADVB)
ONC: Net earnings per share for the last 12 months|HALO - Net earnings per share (EPS TTM)|Revolution Medicines, Inc. (RVMD) - Earnings per share for the last twelve months|Ascentage Pharma Group International - Earnings per share for the trailing year|CGON (CG Oncology Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma Corp URGN|Net earnings per share (EPS TTM) BCAX|Net earnings per share (EPS TTM) personalis.com (PSNL)|Net earnings per share (EPS TTM) ERAS (Erasca)|DCTH: Earnings per share for the last 12 months|YMAB: Net earnings per share for the last 12 months|AURA: Earnings per share for the last twelve months|CADL: Net earnings per share (EPS TTM)|accuray.com (ARAY) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SELLAS Life Sciences Group, Inc.|Earnings per share for the last 12 months ACTU (Actuate Therapeutics Inc.)|Net earnings per share (EPS TTM) CTOR|Net earnings per share for the last 12 months tuhurabio.com HURA|Net earnings per share (EPS TTM) TARA (Protara Therapeutics)|fatetherapeutics.com (FATE) - Net earnings per one share for the last twelve months|Aadi Bio - Net earnings per share (EPS TTM)|TCRX (TScan Therapeutics) - Earnings per share for the last 12 months|CSBR (championsoncology.com) - Net earnings per share for the last 12 months|XBiotech - Earnings per share for the trailing year|CVM (CEL-SCI Corp.) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months OSTX|Net earnings per share (EPS TTM) RADX|Net earnings per share for the last four quarters artivabio.com|Earnings per share for the last twelve months Adlai Nortye ANL|Veru Corporation (VERU) - Net earnings per one share for the last twelve months|TPST - Earnings per share for the last twelve months|Xilio Therapeutics, Inc. (XLO) - Net earnings per share for the last 12 months|RENB: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Mural Oncology (MURA)|KAPA (Kairos Pharma Limited) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months OKUR (OnKure)|Net earnings per share for the last 12 months GDTC (CytoMed Therapeutics)|CRIS (curis.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) APLM (Apollomics)|Net earnings per share for the last four quarters Tharimmune Inc (THAR)|GNPX - Earnings per share for the last twelve months|CLDI (Calidi Biotherapeutics) - Earnings per share for the last 12 months|SBFM: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Purple Biotech Ltd|Net earnings per share (EPS TTM) AONC|BeiGene Ltd - Earnings per share for the last 12 months|Checkpoint Therapeutics - Net earnings per share for the last 12 months|elevationoncology.com - Earnings per share for the last twelve months|iCAD Corp - Net earnings per share (EPS TTM)|IKNA: Earnings per share for the last twelve months|NTBL: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Viracta Therapeutics, Inc.|MOR (MorphoSys AG) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) nayabiosciences.com|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
